-
Xianju Pharmaceutical's Flumazenil Injection Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2022-01-25
On January 11, Xianju Pharmaceutical announced that it had recently received the "Approval Notice for Supplementary Drug Application" for Flumazenil Injection approved and issued by the State Food and Drug Administration.
Flumazenil Injection passed the same generic drug.
-
The listing application of Huachun Bio/Sinopharm Dezhong Traditional Chinese Medicine Class 1 new drug, Prince Shenyue Capsule, was accepted
Time of Update: 2022-01-25
Sales of terminal nervous system Chinese patent medicines in physical pharmacies in Chinese cities (unit: 10,000 yuan)Source: Minet.
2020 China's urban physical pharmacy terminal nervous system Chinese patent medicine TOP5 productsSource: Minet.
-
Happy New Year!
Time of Update: 2022-01-25
According to news on January 10, the next step is to promote the normalization and institutionalization of centralized and volume-based procurement and accelerate the expansion of coverage, and continue to reduce the price of medicines to benefit patients .
-
2022 will be a year of accelerated reshuffle in the pharmaceutical industry
Time of Update: 2022-01-25
The industry pointed out that, especially under the normalization of centralized procurement, pharmaceutical equipment companies will accelerate their transformation towards innovation, and it is expected that small and medium-sized enterprises with weak R&D capabilities will accelerate their elimination .
-
The anti-ED drug market has huge development potential and is attracting domestic pharmaceutical companies to "grab food"
Time of Update: 2022-01-25
However, it should be noted that although China's anti-ED drug industry has been in a stage of rapid development in recent years, there is still a long way to go with the penetration rate of developed countries.
-
Hengrui Medicine's Haitrombopag Ethanolamine Tablets Obtained the Qualification of US FDA Clinical Trial
Time of Update: 2022-01-25
Hetrombopag ethanolamine tablets were approved by the State Drug Administration to conduct clinical trials for the treatment of aplastic anemia in December 2017 (announcement number: Lin 2017-080), and in August 2019, they were approved to carry out tumor chemotherapy-induced thrombocytopenia The clinical trial of CIT (Announcement No.
-
The field of children's medicine is attracting major pharmaceutical companies to accelerate their deployment!
Time of Update: 2022-01-25
For another example, in the field of drugs that are clinically scarce for children with rare diseases in China, on December 17, 2021, Sunflower Pharmaceuticals and Dr.
, certain support from policy and economic levels has been given, which has increased the confidence of enterprises in R&D and production of children's medicines .
-
The State Food and Drug Administration released the catalogue of the 50th batch of generic drug reference preparations
Time of Update: 2022-01-25
It involves 70 kinds of medicines , including alfacalcidol drops, sodium citrate hemofiltration replacement fluid, and propranolol hydrochloride sustained-release capsules .
It involves 70 kinds of medicines , including alfacalcidol drops, sodium citrate hemofiltration replacement fluid, and propranolol hydrochloride sustained-release capsules .
-
From cyclical to high prosperity growth, the pharmaceutical equipment industry starts a new journey
Time of Update: 2022-01-25
According to a set of data released in the Guosen Securities report, the compound growth rate of China's high-end pharmaceutical equipment market from 2015 to 2019 is 18.
-
The wave of innovative drugs is approaching, who can take the lead in the internationalization of the sea of stars?
Time of Update: 2022-01-25
In his sharing, Liu Zexu said that if the proportion of domestic innovative drugs in the pharmaceutical industry increases from 8% to 30% by 2025, the market increment space for the entire innovative drug industry will exceed 600 billion yuan in the future .
-
Ambroxol hydrochloride oral solution, a subsidiary of Hengrui Medicine, was approved for marketing
Time of Update: 2022-01-25
The approved drug Ambroxol Hydrochloride Oral Liquid can increase the secretion of mucous glands in the respiratory tract and reduce the secretion of mucous glands, thereby reducing the viscosity of sputum, and at the same time promoting the secretion of pulmonary surfactant, increasing the movement of bronchial cilia to make sputum easier to cough up, suitable for For acute and chronic bronchitis caused by thick sputum, difficult expectoration .
-
27 domestic innovative drugs will be launched in 2021, reaching new heights
Time of Update: 2022-01-25
Among them, six pharmaceutical companies, including Hengrui Pharmaceutical, Fosun Pharmaceutical, Mindray Medical, Junshi Bio, Shanghai Pharmaceuticals, and Kelun Pharmaceutical, have invested more than 1 billion yuan in research and development .
-
The Internet medical sector rose, and the stock prices of many companies rose sharply
Time of Update: 2022-01-25
However, under the background of the cold online consultation mode and the tightening of supervision on Internet medical care, while the competition of a large number of Internet medical enterprises has become more and more fierce, the stock price and performance have also begun to slow down or even "encountered" .
-
CDE issued 5 guiding principles involving traditional Chinese medicine, improved new drugs, innovative drugs, etc.
Time of Update: 2022-01-25
The details are as follows: Under the deployment of the State Drug Administration, the Center for Drug Evaluation organized the formulation of the "Technical Guidelines for the Study of Samples for Toxicology Research of New Chinese Medicines (for Trial Implementation)" (see attachment) .
-
In 2021, a large number of domestic innovative drugs will be terminated
Time of Update: 2022-01-25
On December 28, Fosun Pharma announced that its subsidiary Jiangsu Wanbang had decided to terminate the clinical trial and subsequent development of the SGLT-2 inhibitor vanpagliflozin .
-
Potential "first-in-class" new drug approved for clinical use in China
Time of Update: 2022-01-25
TextPharmaceutical GuanlanRecently, the website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that a new class 1 drug named PH94B nasal spray has obtained an implied license for clinical trials and is intended to be developed for: adult social anxiety disorder (SAD) anxiety symptoms .
-
Nearly 80% of the new total market capitalization of pharmaceutical companies has increased compared to when they were first listed, with 2 companies increasing by more than 10,000%
Time of Update: 2022-01-25
For example, on the product side, Pien Tze Huang Pharma has invested heavily in innovative research and development, made efforts to master the core technologies of the industrial chain, and strengthened cooperation with many universities and scientific research institutions at home and abroad.
-
The first clinical report of TIGIT monoclonal antibody of Kangfang Bio
Time of Update: 2022-01-25
Source: CDE official websiteAK127 is a TIGIT monoclonal antibody independently developed by the company.
According to the Insight database, there are 7 TIGIT monoclonal antibodies and 4 double-antibodies under development in China.
At present, there are 9 TIGIT monoclonal antibody projects in clinical development in China .
-
Sialon Pharmaceutical's Milrinone Injection Obtained Approval for Supplemental Drug Application
Time of Update: 2022-01-25
On January 10, Sailong Pharmaceutical Group Co.
announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co.
, has recently obtained the “Approval for Supplementary Drug Application for Milrinone Injection” approved and issued by the State Drug Administration.
-
Eli Lilly's "baricitinib" new indication was listed in domestic reports
Time of Update: 2022-01-25
In July 2019, the State Drug Administration approved the marketing of baricitinib tablets for the treatment of moderately to severely active rheumatoid arthritis in adults, with the trade name of elemin .
